Clinical Trial: Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Metastatic Triple-Negative Breast Cancer
Study Type: INTERVENTIONAL
Official Title: ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
Brief Summary:
The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer.The main questions it aims to answer are:to evaluate the anti-cancer efficacy (assess how well it works)to evaluate the safety and tolerability (how well the body can handle the treatment) of this combination of anti-cancer therapy
Read more